Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EBIT: 2023-2025

Historic EBIT for Camp4 Therapeutics (CAMP) over the last 2 years, with Sep 2025 value amounting to -$13.7 million.

  • Camp4 Therapeutics' EBIT fell 1.00% to -$13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.8 million, marking a year-over-year decrease of 2.44%. This contributed to the annual value of -$53.1 million for FY2024, which is 2.33% down from last year.
  • According to the latest figures from Q3 2025, Camp4 Therapeutics' EBIT is -$13.7 million, which was down 4.78% from -$13.0 million recorded in Q2 2025.
  • Camp4 Therapeutics' EBIT's 5-year high stood at -$12.3 million during Q3 2023, with a 5-year trough of -$14.0 million in Q4 2024.
  • In the last 3 years, Camp4 Therapeutics' EBIT had a median value of -$13.1 million in 2025 and averaged -$13.2 million.
  • Data for Camp4 Therapeutics' EBIT shows a maximum YoY decreased of 9.55% (in 2024) over the last 5 years.
  • Over the past 3 years, Camp4 Therapeutics' EBIT (Quarterly) stood at -$13.5 million in 2023, then fell by 4.14% to -$14.0 million in 2024, then fell by 1.00% to -$13.7 million in 2025.
  • Its EBIT stands at -$13.7 million for Q3 2025, versus -$13.0 million for Q2 2025 and -$13.1 million for Q1 2025.